Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc.verified

RETA

Price:

$172.36

Market Cap:

$6.57B

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental ...[Read more]

Industry

Biotechnology

IPO Date

2016-05-26

Stock Exchange

NASDAQ

Ticker

RETA

The PE Ratio as of July 2024 (TTM) for Reata Pharmaceuticals, Inc. (RETA) is -66.29

According to Reata Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -66.29. This represents a change of 2.81% compared to the average of -2.28 of the last 4 quarters.

Reata Pharmaceuticals, Inc. (RETA) Historical PE Ratio (quarterly & annually)

How has RETA PE Ratio performed in the past?

The mean historical PE Ratio of Reata Pharmaceuticals, Inc. over the last ten years is -9.62. The current -66.29 PE Ratio has changed 68.83% with respect to the historical average. Over the past ten years (40 quarters), RETA's PE Ratio was at its highest in in the March 2018 quarter at 32.85. The PE Ratio was at its lowest in in the March 2016 quarter at -253.27.

Quarterly (TTM)
Annual

Average

-9.62

Median

-15.52

Minimum

-69.47

Maximum

104.33

Reata Pharmaceuticals, Inc. (RETA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Reata Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 40.13%

Maximum Annual PE Ratio = 104.33

Minimum Annual Increase = -5195.07%

Minimum Annual PE Ratio = -69.47

Quarterly (TTM)
Annual
YearPE RatioChange
2022-4.4237.36%
2021-3.22-80.85%
2020-16.82-21.50%
2019-21.4311.06%
2018-19.2935.70%
2017-14.22-79.53%
2016-69.4740.13%
2015-49.58-147.52%
2014104.33-5195.07%

Reata Pharmaceuticals, Inc. (RETA) Average PE Ratio

How has RETA PE Ratio performed in the past?

The current PE Ratio of Reata Pharmaceuticals, Inc. (RETA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-8.15

5-year avg

-13.04

10-year avg

-9.62

Reata Pharmaceuticals, Inc. (RETA) PE Ratio vs. Peers

How is RETA’s PE Ratio compared to its peers?

Reata Pharmaceuticals, Inc.’s PE Ratio is less than Sarepta Therapeutics, Inc. (809.97), less than Mirati Therapeutics, Inc. (-5.32), less than Krystal Biotech, Inc. (100.81), less than Intercept Pharmaceuticals, Inc. (-13.55), less than PTC Therapeutics, Inc. (0), less than Madrigal Pharmaceuticals, Inc. (-4.31), less than CureVac N.V. (-12.93), less than Vir Biotechnology, Inc. (-2.79), less than Propanc Biopharma, Inc. (-2.52), less than Viking Therapeutics, Inc. (-0.02), less than Terns Pharmaceuticals, Inc. (-56.19), less than Akero Therapeutics, Inc. (-6.93), less than null (-8.85),

Build a custom stock screener for Reata Pharmaceuticals, Inc. (RETA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Reata Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Reata Pharmaceuticals, Inc. (RETA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Reata Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Reata Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Reata Pharmaceuticals, Inc. (RETA)?

What is the highest PE Ratio for Reata Pharmaceuticals, Inc. (RETA)?

What is the 3-year average PE Ratio for Reata Pharmaceuticals, Inc. (RETA)?

What is the 5-year average PE Ratio for Reata Pharmaceuticals, Inc. (RETA)?

How does the current PE Ratio for Reata Pharmaceuticals, Inc. (RETA) compare to its historical average?